![Thomas Sabia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Perfil
Thomas Sabia formerly worked at Quince Therapeutics SpA, as Chief Commercial Officer from 2022 to 2023 and Quince Therapeutics, Inc., as Chief Commercial Officer from 2022 to 2025.
Mr. Sabia received his undergraduate degree and Masters Business Admin degree from Salisbury State University.
Antiguos cargos conocidos de Thomas Sabia.
| Empresas | Cargo | Fin |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Corporate Officer/Principal | 28/02/2025 |
EryDel SpA
 EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Corporate Officer/Principal | 01/10/2023 |
Formación de Thomas Sabia.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
5
Relaciones de 1er grado
3
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
Salisbury State University
 Salisbury State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EryDel SpA
EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Health Technology |
Quince Therapeutics, Inc.
 Quince Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops drugs for the treatment of central nervous system disorders and Alzheimer’s diseases | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Sabia
